Effects of patient preferences on outcomes in the predictors of remission in depression to individual and combined treatments (PReDICT) Study

American Journal of Psychiatry

Volumn 174, Issue 6, 2017, Pages 546-556

  Dunlop, Boadie W ^a,b,c,d,e,f   Kelley, Mary E ^a,b,c,d,e,f   Aponte Rivera, Vivianne ^a,b,c,d,e,f   Mletzko Crowe, Tanja ^a,b,c,d,e,f   Kinkead, Becky ^a,b,c,d,e,f   Ritchie, James C ^a,b,c,d,e,f   Nemeroff, Charles B ^a,b,c,d,e,f   Craighead, W Edward ^a,b,c,d,e,f   Mayberg, Helen S ^a,b,c,d,e,f   Alvarez, Carla ^d   Etzel, Julie ^d   Falero, Rosario ^d   Gerardi, Maryrose ^d   Heekin, Mary ^d   Jones, Meredith ^d   Lim, Noriel ^d   Mahoney, Vivianna ^d   Ramirez, Cynthia ^d   Reddy, Sheethal ^d   Ritschel, Lorie ^d   Rosenberg, Jill ^d   Simeonova, Diana ^d   Sylvers, Patrick ^d   Zagoloff, Alexandra ^d   Craighead, Linda Wilcoxon ^d   Almeida, Nicole ^d   Beck, Corey ^d   Garlow, Steve ^d   Haroon, Ebrahim ^d   Jacob, Maryann ^d   Rakofsky, Jeffrey ^d   Wint, Dylan ^d   Betancourt, Yara ^d   Blastos, Beatriz ^d   Chismar, Ronald ^d   Galanti, Melanie ^d   Gibson, Rachelle ^d   Marx, Lauren ^d   McKenzie, Melissa ^d   Crowe, Tanja Mletzko ^d   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of Psychiatry and Behavioral Sciences ^*

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; ESCITALOPRAM; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFICACY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT PREFERENCE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PSYCHOTHERAPY; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; COGNITIVE THERAPY; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PREFERENCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; TREATMENT OUTCOME;

EID: 85020117872     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16050517     Document Type: Article

References (56)

1. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. Washington, DC, American Psychiatric Publishing, 2010, pp 17
2. Weitz E, Hollon SD, Twisk J, et al: Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-Analysis. JAMA Psychiatry 2015; 72:1102-1109
3. Collins FS, Varmus H:Anewinitiative on precision medicine.NEngl J Med 2015; 372:793-795
4. Kapur S, Phillips AG, Insel TR:Whyhas it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012; 17:1174-1179
5. Sotsky SM, Glass DR, Shea MT, et al: Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1991; 148:997-1008
6. Nemeroff CB, Heim CM, Thase ME, et al: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003; 100:14293-14296
7. Leykin Y, Amsterdam JD, DeRubeis RJ, et al: Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 2007; 75:267-276
8. Fournier JC, DeRubeis RJ, Shelton RC, et al: Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 2009; 77:775-787
9. WallaceML,Frank E, Kraemer HC:Anovel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 2013; 70:1241-1247
10. Kemp AH, Gordon E, Rush AJ, et al: Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008; 13:1066-1086
11. McGrath CL, Kelley ME, Holtzheimer PE, et al: Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013; 70:821-829
12. Dunlop BW, Kelley ME, McGrath CL, et al: Preliminary findings supporting insula metabolic activity as a predictor of outcome to psychotherapy and medication treatments for depression. J Neuropsychiatry Clin Neurosci 2015; 27:237-239
13. McHughRK, Whitton SW,Peckham AD, et al: Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-Analytic review. J Clin Psychiatry 2013; 74:595-602
14. Dwight-Johnson M, Lagomasino IT, Hay J, et al: Effectiveness of collaborative care in addressing depression treatment preferences among low-income Latinos. Psychiatr Serv 2010; 61:1112-1118
15. Cooper LA, Gonzales JJ, Gallo JJ, et al: The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care 2003; 41:479-489
16. Bedi N, Chilvers C, Churchill R, et al: Assessing effectiveness of treatment of depression in primary care. Partially randomised preference trial. Br J Psychiatry 2000; 177:312-318
17. Winter SE, Barber JP: Should treatment for depression be based more on patient preference? Patient Prefer Adherence 2013; 7: 1047-1057
18. Swift JK, Callahan JL: The impact of client treatment preferences on outcome: a meta-Analysis. J Clin Psychol 2009; 65:368-381
19. Lindhiem O, Bennett CB, Trentacosta CJ, et al: Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-Analysis. Clin Psychol Rev 2014; 34:506-517
20. Hunter AM, Cook IA, Tartter M, et al: Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder. Psychopharmacology (Berl) 2015; 232: 3833-3840
21. Weiner IB, Stricker G, Widiger TA, Behavior therapy and cognitivebehavioral therapy, Handbook of Psychology, vol. 8. 2nd ed: Clinical Psychology. Hoboken, NJ, Wiley, 2013, pp 291-319
22. Kraus DR, Castonguay L, Boswell JF, et al: Therapist effectiveness: implications for accountability and patient care. Psychother Res 2011; 21:267-276
23. Bhagwagar Z, Cowen PJ: 'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol Med 2008; 38:307-313
24. Parsey RV, Oquendo MA, Ogden RT, et al: Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006; 59:106-113
25. Dunlop BW, Kelley ME, Mletzko TC, et al: Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. J Psychiatr Res 2012; 46:375-381
26. Dunlop BW, Binder EB, Cubells JF, et al: Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT): study protocol for a randomized controlled trial. Trials 2012; 13:106
27. Aponte-Rivera V, Dunlop BW, Ramirez C, et al: Enhancing Hispanic participation in mental health clinical research: development of a Spanish-speaking depression research site. Depress Anxiety 2014; 31:258-267
28. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
29. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2. 0). New York, Biometrics Research Department, New York State Psychiatric Institute, 1995
30. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
31. Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
32. Rush AJ, Trivedi MH, Ibrahim HM, et al: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573-583
33. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
34. Beck AT, Rush AJ, ShawBF, et al: Cognitive Therapy of Depression. New York, Guilford, 1979
35. Young J, Beck AT: Cognitive Therapy Scale: Rating Manual. Philadelphia, University of Pennsylvania, 1980
36. DeRubeis RJ, Hollon SD, Amsterdam JD, et al: Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005; 62:409-416
37. Elkin I, Shea MT, Watkins JT, et al: National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-982
38. Keller MB, McCullough JP, Klein DN, et al: A comparison of nefazodone, the cognitive behavioral-Analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462-1470
39. Dimidjian S, Hollon SD, Dobson KS, et al: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74:658-670
40. Frank E, Cassano GB, Rucci P, et al: Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy. Psychol Med 2011; 41: 151-162
41. Dobscha SK, Corson K, Gerrity MS: Depression treatment preferences of VA primary care patients. Psychosomatics 2007; 48: 482-488
42. Leykin Y, Derubeis RJ, Gallop R, et al: The relation of patients' treatment preferences to outcome in a randomized clinical trial. Behav Ther 2007; 38:209-217
43. Raue PJ, Schulberg HC, Heo M, et al: Patients' depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study. Psychiatr Serv 2009; 60:337-343
44. Kwan BM, Dimidjian S, Rizvi SL: Treatment preference, engagement, and clinical improvement in pharmacotherapy versus psychotherapy for depression. Behav Res Ther 2010; 48: 799-804
45. Dunlop BW, Rajendra JK, Craighead WE, et al: Functional connectivity of the subcallosal cingulate cortex and differential outcomes to treatment with cognitive-behavioral therapy or antidepressant medication for major depressive disorder. AmJ Psychiatry 2017; 174: 533-545
46. Van HL, Dekker J, Koelen J, et al: Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression. Psychother Res 2009; 19:205-212
47. Kocsis JH, Leon AC, Markowitz JC, et al: Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 2009; 70: 354-361
48. Mergl R, Henkel V, Allgaier AK, et al: Are treatment preferences relevant in response to serotonergic antidepressants and cognitivebehavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients' choice arm. Psychother Psychosom 2011; 80:39-47
49. Steidtmann D, Manber R, Arnow BA, et al: Patient treatment preference as a predictor of response and attrition in treatment for chronic depression. Depress Anxiety 2012; 29:896-905
50. Elkin I, Gibbons RD, Shea MT, et al: Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative ResearchProgram.J Consult Clin Psychol 1995; 63:841-847
51. Iacoviello BM, McCarthy KS, Barrett MS, et al: Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials. J Consult Clin Psychol 2007; 75:194-198
52. Jacobson NS, Hollon SD: Cognitive-behavior therapy versus pharmacotherapy: Now that the jury's returned its verdict, it's time to present the rest of the evidence. J Consult Clin Psychol 1996; 64: 74-80
53. Creed TA, Wolk CB, Feinberg B, et al: Beyond the label: Relationship between community therapists' self-report of a cognitive behavioral therapy orientation and observed skills. Adm Policy Ment Health Ment Health Serv Res 2016; 43:36-43
54. Warden D, Trivedi MH, Wisniewski SR, et al: Identifying risk for attrition during treatment for depression. Psychother Psychosom 2009; 78:372-379
55. Owens MJ, Dunlop BW, Plott S, et al: Poster presentation: Estimates of serotonin or norepinephrine transporter occupancydonot predict efficacy in a 12 week trial. Presented at the proceedings of the 54th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, Fla, 2015
56. Menke A, Arloth J, Best J, et al: Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. Psychoneuroendocrinology 2016; 69:161-171